-19.7%
TSCO vs MRNA
+34.8%
-54.5%
-52.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.5% | +5.4% | -6.9% | -1.6% |
| 7D | -5.7% | -1.1% | -4.6% | -5.6% |
| 30D | -8.8% | +126.1% | -134.9% | -12.2% |
| 3M | +6.3% | +190.0% | -183.7% | +0.5% |
| 6M | -32.3% | +157.2% | -189.5% | -35.6% |
| YTD | -32.7% | +388.2% | -420.9% | -39.1% |
| 1Y | -43.7% | +467.0% | -510.7% | -49.8% |
| 3Y | -19.7% | +36.1% | -55.7% | -28.1% |
| All | -19.7% | +34.8% | -54.5% | -28.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling